Blog
RSS FeedPosted by Michael Wonder on 20 Apr 2023
AMA urges pharmacy reform to deliver lower medicine prices
20 April 2023 - The AMA says it’s high time recommendations from more than a dozen expert reports and inquiries over ...
Posted by Michael Wonder on 20 Apr 2023
Updates from the Health Technology Assessment Policy and Methods Review Reference Committee – March and April 2023
20 April 2023 - The Health Technology Assessment Policy and Methods Review Reference Committee met on 24 March 2023 and ...
Posted by Michael Wonder on 16 Apr 2023
Price of a life: Australians wait two years longer for breakthrough medicines than US citizens
16 April 2023 - Australians are waiting two years longer to access new lifesaving subsidised medicines because of pharma giants. Now, ...
Posted by Michael Wonder on 16 Apr 2023
Australian cancer patients spend $200 million a year on treatments not on the PBS and it’s got to change
16 April 2023 - Australian cancer patients were spending in excess of $200m each year of their own money on therapies ...
Posted by Michael Wonder on 12 Apr 2023
HTA reform starts today – consultations open
11 April 2023 - Medicines Australia welcomes the official start of the Health Technology Assessment (HTA) Review consultation that should ...
Posted by Michael Wonder on 11 Apr 2023
Health technology assessment policy and methods review consultation
11 April 2023 - The first round of public consultation for the HTA Review is open. Submissions will be accepted ...
Posted by Michael Wonder on 11 Apr 2023
New life saving medicines
11 April 2023 - The Australian Government has added the two medicines, Kanuma (sebelipase alfa) and Cerdelga (eliglustat) to the Life ...
Posted by Michael Wonder on 10 Apr 2023
Cheaper medicines for graft versus host disease, chronic rhinosinusitis and oesophageal cancer
10 April 2023 - For the first time Jakavi (ruxolitinib) will be listed for the treatment of patients with either acute ...
Posted by Michael Wonder on 06 Apr 2023
Public summary documents – December 2022 PBAC meeting
6 April 2023 - The public summary documents (positive recommendations and subsequent decisions not to recommend) from the December 2022 PBAC ...
Posted by Michael Wonder on 06 Apr 2023
Life changing cystic fibrosis treatment now available to children 6 years and above
6 April 2023 - From 1 May 2023, children aged 6 to 11 with cystic fibrosis will have access to ...
Posted by Michael Wonder on 05 Apr 2023
‘An absolute game changer’: children under 12 to receive life saving drug
6 April 2023 - Hundreds of children with cystic fibrosis will have subsidised access to the life-changing medication Trikafta from ...
Posted by Michael Wonder on 03 Apr 2023
Nucala (mepolizumab) is now listed on the PBS for Australians with chronic rhinosinusitis with nasal polyps
3 April 2023 - Nucala is the first biologic treatment to be PBS-subsidised for the treatment of severe chronic rhinosinusitis with ...
Posted by Michael Wonder on 01 Apr 2023
Schedule of Pharmaceutical Benefits - 1 April 2023
1 April 2023 - The April 2023 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 01 Apr 2023
Outcome statement - February 2023 DUSC meeting
31 March 2023 - The outcome statement from the February 2023 DUSC meeting is now available. ...
Posted by Michael Wonder on 30 Mar 2023
Expanded access to subsidised oral antiviral Paxlovid and other COVID-19 supports
30 March 2023 - From 1 April, more than 160,000 people aged 60 to 69 will have access to the ...